Get 20% Off Journals at LWW.com

Cholestatic hepatitis as a result of severe cortisol deficiency in early infancy: report of two cases and review of literature.

Turk J Pediatr 2006 Oct-Dec;48(4):376-9

Division of Pediatric Endocrinology, Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.

Cholestatic hepatitis is identified as one of the features of hypopituitarism in the newborn, but the exact etiology of cholestasis in these cases has not been well established yet. We report here two infants, one with isolated glucocorticoid deficiency and the other with multiple pituitary hormone deficiency, indicating primary and central adrenal insufficiency, respectively, who presented with recurrent hypoglycemic seizures and cholestatic hepatitis. Severe cortisol deficiency in these cases was suggested to be the cause of cholestatic hepatitis. Review of the literature and our cases showed that the cortisol deficiency in both primary and central adrenal insufficiency occurring only during neonatal and early infancy period cause cholestatic hepatitis. The severity and the age of onset of cortisol deficiency are suggested to be the important predictors of cholestatic hepatitis in childhood.

Download full-text PDF

Source
April 2007
Save 15% Survey

Similar Publications

Nafcillin-Induced Hepatic Injury: A Case Report and Literature Review.

Cureus 2021 Jan 20;13(1):e12817. Epub 2021 Jan 20.

Pathology, University of Missouri Kansas City School of Medicine, Kansas City, USA.

Background: Drug-induced liver injury (DILI) is the most common cause of acute liver failure in the Western world. While it requires a diagnosis of exclusion, it is exceedingly prevalent in patients taking multiple hepatotoxic agents, the foremost of which are antibiotics, followed by herbal and dietary supplements. Below we will discuss a case of nafcillin-induced liver injury suggested by a thorough work-up and rule-out of other hepatic and biliary pathologies. Read More

View Article and Full-Text PDF
January 2021

Incidence, pattern and severity of abnormal liver blood tests among hospitalised patients with SARS-COV2 (COVID-19) in South Wales.

Frontline Gastroenterol 2021 21;12(2):89-94. Epub 2020 Aug 21.

Gwent Liver Unit, Aneurin Bevan University Health Board, Newport, UK.

Introduction: SARS-CoV-2 (COVID-19) is a novel coronavirus that emerged in Wuhan, China in late 2019 and since become a global pandemic. As such, its clinical behaviour is a subject of much interest. Initial reports suggested a significant proportion of patients have abnormal liver blood tests. Read More

View Article and Full-Text PDF

Sonographic findings in coronavirus disease-19 associated liver damage.

PLoS One 2021 19;16(2):e0244781. Epub 2021 Feb 19.

Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Tübingen, Germany.

Purpose: This study was conducted to evaluate the role of liver sonography in patients with coronavirus disease 2019 (COVID-19) and elevated liver enzymes.

Materials And Methods: In this retrospective study, patients tested positive for SARS-CoV-2 in our emergency ward between January 01 and April 24, 2020 and elevated liver enzymes were included (Cohort 1). Additionally, the local radiology information system was screened for sonographies in COVID-19 patients at the intensive care unit in the same period (Cohort 2). Read More

View Article and Full-Text PDF
February 2021

Hepatitis C-positive liver transplantation: outcomes and current practice.

Curr Opin Organ Transplant 2021 Feb 11. Epub 2021 Feb 11.

Liver Transplant Program, Intermountain Medical Center, Murray, Utah, USA.

Purpose Of Review: The coincidence of the opioid epidemic and the approval of direct-acting antivirals for the treatment of hepatitis C virus (HCV) has resulted in an imbalance in HCV viraemic donors relative to HCV viraemic patients awaiting liver transplantation. Although ethical concerns exist about knowingly infecting patients with HCV in the absence of prospective, protocolized studies, transplantation of HCV-positive liver allografts into HCV-negative recipients has increased exponentially in recent years. For this reason, we sought to review outcomes, cost-effectiveness and ethical concerns associated with this practice. Read More

View Article and Full-Text PDF
February 2021

Pharmacological properties of baicalin on liver diseases: a narrative review.

Pharmacol Rep 2021 Feb 17. Epub 2021 Feb 17.

Department of Pharmacy, Tongji Hospital Affiliated Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang avenue, Wuhan, 430030, Hubei, China.

Baicalin is the main active component of Scutellaria baicalensis, widely used in traditional Chinese medicine thanks to its various pharmacological effects, such as anti-tumor, anti-inflammatory, and antibacterial properties, as well as cardiovascular, hepatic, and renal protective effect. Recently, the protective effects of baicalin on liver disease have received much more attention. Several studies showed that baicalin protects against several types of liver diseases including viral hepatitis, fatty liver disease, xenobiotic induced liver injury, cholestatic liver injury, and hepatocellular carcinoma, with a variety of pharmacological mechanisms. Read More

View Article and Full-Text PDF
February 2021